Global News

iCardiac launches spirometry training standardization tool

Thursday, February 2, 2017

iCardiac Technologies, a centralized core laboratory specializing in respiratory and cardiac safety studies, has launched a Direct-to-Subject Pre-Coaching video tool to help minimize the variability in respiratory test data caused by differences in subject technique and technician coaching. The training videos will be embedded in equipment iCardiac sends to all trial sites and are brief enough to be shown to subjects at the beginning of each testing visit.

[Read More]

Charles River Associates acquires C1 Consulting

Wednesday, February 1, 2017

Charles River Associates (CRA), a provider of economic, financial, and management consulting services, has acquired substantially all of the assets of C1 Consulting, a life sciences strategy consulting firm that helps pharmaceutical and biotech clients maximize their business potential through the development of highly tailored commercialization strategies based on advanced analytics, customer insights and therapy area expertise. The newly acquired team will join CRA’s Life Sciences Practice and provide additional breadth, depth, and scale to CRA’s client offerings across the industry. Financial terms of the acquisition were not disclosed. CRA expects the acquisition to be accretive to earnings in fiscal 2017.

[Read More]

FDA grants Priority Review for Genentech’s Actemra

Wednesday, February 1, 2017

Genentech, a member of the Roche Group, announced that the FDA has accepted the company’s Supplemental Biologics License Application (sBLA) for Actemra (tocilizumab) for the treatment of GCA, a chronic, potentially life-threatening autoimmune condition. The FDA also granted Priority Review designation for Actemra for the treatment of giant cell arteritis (GCA). The designation is based on the positive outcome of the phase III GiACTA study evaluating Actemra in people with GCA. Results showed that Actemra, initially combined with a six-month steroid (glucocorticoid) regimen, more effectively sustained remission through one year compared to a six- or 12-month steroid taper regimen given alone in people with GCA.

[Read More]

PixarBio investors launch lawsuit

Wednesday, February 1, 2017

Lawsuit for Investors in shares of PixarBio announced by Shareholders Foundation. The Shareholders Foundation lawsuit was filed on behalf of certain purchasers of shares of PixarBio over alleged Securities Laws Violations by PixarBio.

[Read More]

ESSA Pharma receives $4M from Research Institute of Texas

Wednesday, February 1, 2017

ESSA Pharma, a pharmaceutical company, currently in the clinical development stage, focused on the development of small molecule drugs for the treatment of prostate cancer, announced the receipt of a $4 million payment from the Cancer Prevention Research Institute of Texas (CPRIT). The payment is part of a total non-dilutive grant of $12 million, repayable out of potential product revenues, which was originally awarded in February 29, 2014.

[Read More]

Chiltern expands in Bangalore, India

Wednesday, February 1, 2017

Chiltern, a global CRO, has announced the opening of its new process and technology center in Bangalore, India. The new office is a direct result of the company’s continued success and fulfills a need to further enhance its global data capabilities.

[Read More]